Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada

NCT07718139 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: nivolumab
BIOLOGICAL: pembrolizumab
BIOLOGICAL: durvalumab

Sponsor

Bristol-Myers Squibb